Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

79.48
-2.1800-2.67%
Post-market: 79.480.00000.00%18:55 EST
Volume:1.89M
Turnover:150.01M
Market Cap:12.87B
PE:-49.27
High:82.57
Open:82.24
Low:78.61
Close:81.66
52wk High:86.15
52wk Low:23.95
Shares:161.97M
Float Shares:161.00M
Volume Ratio:0.73
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6132
EPS(LYR):-3.0358
ROE:-40.04%
ROA:-5.68%
PB:20.83
PE(LYR):-26.18

Loading ...

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

TIPRANKS
·
1 hour ago

BRIEF-Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA

Reuters
·
Yesterday

Biogen Receives European Commission Approval for High Dose Regimen of Spinraza® (Nusinersen) for Spinal Muscular Atrophy

THOMSON REUTERS
·
Yesterday

Biogen - High Dose Spinraza Approved in Japan, Decision Expected by April 3, 2026

THOMSON REUTERS
·
Yesterday

Ionis Pharmaceuticals raises TRYNGOLZA peak sales guidance to over $2 billion for sHTG

Reuters
·
Jan 12

Ionis Pharmaceuticals Announces 2025 Achievements and Outlines 2026 Milestones

Reuters
·
Jan 12

Ionis Pharmaceuticals EVP Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Jan 10

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

BUZZ-Ionis hits seven-year high after partner GSK reveals promising hepatitis B trial results

Reuters
·
Jan 08

GSK's chronic hepatitis B therapy shows promise in key studies, analysts await full data

Reuters
·
Jan 07

Ionis and GSK Report Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B

Reuters
·
Jan 07

Ionis Partner GSK Announces Positive Topline Results From B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen, a Potential First-in-Class Medicine for Chronic Hepatitis B

THOMSON REUTERS
·
Jan 07

Ionis Pharmaceuticals EVP Research Eric Swayze Reports Sale of Common Shares

Reuters
·
Jan 07

Ionis Pharmaceuticals Files Initial Beneficial Ownership Statement for Holly B. Kordasiewicz, EVP and Chief Development Officer

Reuters
·
Jan 07

Ionis Pharmaceuticals CEO to Present Company Overview at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Assessing Ionis Pharmaceuticals (IONS) Valuation After Analyst Optimism And FDA Approval Of Tryngolza

Simply Wall St.
·
Jan 06

Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 06

The Year-End 2025 Biotech Rally And What It Means For 2026

Benzinga_recent_news
·
Dec 31, 2025

Will FDA Approval of Tryngolza and Analyst Support Change Ionis Pharmaceuticals' (IONS) Narrative?

Simply Wall St.
·
Dec 22, 2025

Cathie Wood Dumps $11 Milllion Worth of Tesla Stock While Doubling Down on These Notable Crypto Plays

Benzinga
·
Dec 19, 2025